2. Objectives of this session-
ā¢Describe the mechanism of action, antibacterial spectrum,
uses and side effects of Carbapenems.
ā¢Name some important Carbapenems.
8. Limitation :
ā¢ Rapid hydrolysis by enzyme dehydropeptidase (dipeptidase)
present in renal proximal tubule.
ā¢ Forms metabolites toxic to renal tubules.
ā¢ Combined with cilastatin, a reversible inhibitor of
dehydropeptidase .
ā¢ Always used in combination with cilastatin as FDC.
9. Uses :
ā¢ UTI ( including Pseudomonas)
ā¢ Pneumonia ( including resistant Streptococci)
ā¢ Skin, soft tissue, bone and joint infections (Staph.aureus)
ā¢ Pelvic/abdominal infection/sepsis
ā¢ Gram negative septicemia
ā¢ Serious hospital acquired infections
Adverse effects:
ļ§ Nausea and vomiting
ļ§ Seizures at higher doses.
10. MEROPENEM
ļ¼Similar to imipenem.
ļ¼Not destroyed by renal dipeptidase.
ļ¼Risk of seizures is less than with Imipenem.
ļ¼Indications are similar to imipenem.
11. ERTAPENEM
ā¢Similar to meropenem except it is not useful against
P.aeruginosa.
ā¢Longest t Ā½ of 4 hrs amongst carbapenems - given once
daily.
14. Spectrum
ā¢ Aerobic gram āve bacteria
ā¢ No activity against gram +ve bacteria or anaerobes.
ā¢ Resistant to many Ī² lactamases except extended spectrum Ī²
lactamases .
15. Pharmacokinetics
ā¢ Oral BA poor ļ IM /IV
ā¢ Inhalational Aztreonam ā Cystic Fibrosis due to P. aeruginosa
ā¢ Achieves therapeutic conc. in CSF in the presence of inflamed
meninges ļ alternative to cephalosporins in the Rx of meningitis
caused by gram āve bacilli
ā¢ Excreted in the urine
17. To summarize
ā¢Important drugs under carbapenems
ā¢Limitation of imipenem
ā¢Advantages of meropenem over imipenem
ā¢Carbapenem with longest t Ā½
ā¢Orally effective carbapenem
ā¢Aztreonam- spectrum of action, pharmacokinetics .